4-methoxymethyl-2-methylthiopyrimidine | 123061-70-1

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 4-methoxymethyl-2-methylthiopyrimidine
• 英文别名: 4-(Methoxymethyl)-2-methylsulfanylpyrimidine
• CAS: 123061-70-1
• 化学式: C₇H₁₀N₂OS
• 分子量: 170.235
• InChiKey: QHEAYFATNDQOKX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  60.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-Methoxymethyl-2-methylsulfanyl-pyrimidine-5-carboxylic acid methyl ester 在 sodium hydroxide 作用下， 反应 2.0h， 生成 4-methoxymethyl-2-methylthiopyrimidine
  参考文献：
  名称：

  Sansebastiano; Mosti; Menozzi, Il Farmaco, 1993, vol. 48, # 3, p. 335 - 355

  摘要：

  DOI：

文献信息

• Stannylation reaction and cross-couplings in pyrimidines
  作者：Amera J. Majeed、Øyvind Antonsen、Tore Benneche、Kjell Undheim

  DOI：10.1016/0040-4020(89)80011-0

  日期：1989.1

  The stannylated pyrimidines form new carbon-carbon bonds by Pd(II)-catalyzed cross-couplings, tert-Butyldimethylsilyl-, dimethylthexylsilyl- and tert-butyldiphenylsilyl-oxymethyl (tri-n-butyl)tin have been synthesized and used in Pd(II)-catalyzed cross-coupling reactions with 4-chloropyrimidines. The silyi groups were not cleaved off during exposure to fluoride ions in aqueous media but were readily removed

  嘧啶已通过相应的car☐yyl有机锡酯的热去甲酰基化反应而在活化的4-位上被甲锡烷基化。十烷基化可通过双（乙腈）二氯化钯（II）催化。4- Iodopyrimidines要么4- stannylated通过取代反应与三Ñ -butyltin -铜或通过偶联用六甲基或六正丁基二锡和Pd（II）催化的反应。甲锡基嘧啶通过Pd（II）催化的交叉偶联形成叔碳新的碳-碳键，叔丁基二甲基甲硅烷基-，二甲基甲氧基甲硅烷基-和叔丁基二苯基甲硅烷基-氧甲基（tri- n已经合成了丁基丁基锡，并将其用于Pd（II）催化的与4-氯嘧啶的交叉偶联反应中。在含水介质中暴露于氟离子的过程中，未除去硅烷基，但很容易被THF中的氟离子除去，从而得到4-羟甲基嘧啶。
• MAJEED, AMERA J.;ANTONSEN, ZHIAMETRYVIND;BENNECHE, TORE;UNDNEIM, KJELL, TETRAHEDRON, 45,(1989) N, C. 993-1006
  作者：MAJEED, AMERA J.、ANTONSEN, ZHIAMETRYVIND、BENNECHE, TORE、UNDNEIM, KJELL

  DOI：——

  日期：——
• CARBOCYCLIC SULFONE ROR GAMMA MODULATORS
  申请人：BRISTROL-MYERS SQUIBB COMPANY

  公开号：US20160326103A1

  公开（公告）日：2016-11-10

  Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders.
• US9771320B2
  申请人：——

  公开号：US9771320B2

  公开（公告）日：2017-09-26